含噻替哌预处理方案用于自体干细胞移植的长期结果

Autologous stem cell transplantation (ASCT) remains a cornerstone in the treatment of both Hodgkin lymphoma (HL) and various non-Hodgkin lymphoma (NHL) subtypes. BEAM (carmustine, etoposide, cytarabine, and melphalan) is the most frequently used conditioning regimen; however, owing due to limited availability and toxicity of carmustine, thiotepa-containing regimens have been suggested.

We previously reported encouraging results in ASCT with a TECAM (thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan) conditioning regimen from 2000 to 2013.

We aimed to update our experience with the TECAM regimen by adding our experience from 2013 to 2020 to the previously reported cohort.

Moreover, we aimed to use the detailed data for the 2 transplant cohorts to identify improvements in ASCT outcomes in the recent era.

We retrospectively analyzed all lymphoma patients who underwent ASCT at our center between January 2000 and December 2020. A total of 353 lymphoma patients were included (142 in the newer cohort added to 211 previously reported patients), all of whom were treated with our standard TECAM conditioning regimen. The cohort included 127 patients with HL, 107 with DLBCL, and 119 with other NHL subtypes. The newer cohort was characterized by significantly poorer Eastern Cooperative Oncology Group Performance Status (ECOG-PS) prior to ASCT (45. 7% versus 19. 3% with ECOG-PS ≥1; P < . 01), whereas a higher proportion of patients entered transplantation in complete response (CR) (71. 9% versus 47. 8%; P < . 01). The median follow-up after ASCT was 136. 4 months (95% confidence interval [CI], 91. 4 to 181. 4 months). The 3-year progression-free survival (PFS) and overall survival (OS) rates post-ASCT for the entire cohort were 59. 8% and 79. 3%, respectively. Evaluating the 303 of 353 patients (86.

4%) who entered ASCT with a responsive disease-a population that represents today's approach to the selection of patients for ASCT-the 3-year PFS and OS rates were 61. 5% and 81. 9%, respectively. In this population, the 3-year PFS rate was 62. 2% for HL, 62. 6% for DLBCL, 64. 3% for primary central nervous system lymphoma (PCNSL), and the 3-year OS rate were 90. 1%, 75. 2%, and 78. 6%, respectively. OS was significantly better in the newer cohort (P < . 01), but not when evaluating only patients who entered ASCT with responsive disease.

Dose reductions, poor disease status, and poor ECOG-PS at ASCT entry were associated with worse outcomes across all lymphoma subtypes. In accordance with our previous report, patients entering transplantation for DLBCL with a partial response achieved similar outcomes as those with a CR. Eighteen patients died within the first 100 days, 8 due to disease progression and 10 due to transplantation-related complications (2. 8%). There were no cases of interstitial pneumonitis syndrome. Twenty-two cases (6. 2%) of secondary malignancies were documented.

Our results confirm that TECAM is an effective and safe conditioning regimen for ASCT in patients with HL and various NHLs, including favorable results in PCNSL. Despite a higher proportion of frail patients, the newer cohort's outcomes were favorable, driven by better lymphoma control pretransplantation. In the DLBCL cohort, ECOG-PS had more prognostic value than achieving a CR pre-ASCT, a finding relevant to the optimal allocation of patients to different treatment options in the era of chimeric antigen receptor T cell availability.